Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chloramphenicol is a broad-spectrum antibiotic originally derived from the bacterium *Streptomyces venezuelae* and now produced synthetically. It is primarily used to treat serious bacterial infections, including typhoid fever, bacterial conjunctivitis, cholera and other life-threatening infections when other antibiotics are ineffective or contraindicated. Its use is limited due to the risk of severe side effects such as bone marrow suppression and aplastic anemia. Chloramphenicol acts by binding to the 50S subunit of the bacterial ribosome, inhibiting peptidyl transferase activity and thus blocking protein synthesis in susceptible bacteria.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chloramphenicol.